HeartBeam, Inc. announced first patient enrollments in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. The study is designed to enroll 100 emergency room patients presenting with chest pain and compare readings from the HeartBeam device and a standard 12-lead ECG against each patient’s final diagnosis at discharge. No results from ALIGN-ACS have been reported yet; the company said findings will be used to inform the design of a future multicenter pivotal study intended to support a potential FDA submission.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartbeam Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260305231175) on March 05, 2026, and is solely responsible for the information contained therein.
Comments